Coronavirus disease 2019 (COVID-19) is a novel infectious disease that has spread worldwide. In the United States, COVID-19 disproportionately affects racial and ethnic minorities, particularly African Americans, with an observed 2-fold higher rate for hospitalization and greater than 2-fold higher rate for death as compared with White Americans. The disparity seen with COVID-19 is consistent with patterns of disparities observed for cancer; it is well documented that 5-year survival rates for multiple cancers are lower in African Americans compared with White Americans. Root cause contributions for the disparity overlap between COVID-19 and cancer. While cancer is a genetic disease that is influenced by tissue microenvironment, COVID-19 is an infectious disease that is enabled by cellular expression of angiotensin-converting enzyme 2 receptors. However, socioeconomic disadvantages, level of education, lifestyle factors, health comorbidities, and limited access to medical care appear to fuel underlying risk for both cancer and COVID-19 disparities. In addition to African Americans demonstrating higher risk of acquiring and dying from either disease, they are underrepresented in clinical trials involving cancer or COVID-19. Long-term disparities are present with survivorship from cancer and may be likely with survivorship from COVID-19; both have revealed untoward effects on postdiagnosis economic viability for African Americans. Collaborative strategies that include community engagement, diverse participation in cancer and COVID-19 clinical trials, providing insurance for affected persons who lost employment due to either disease, and supporting safety-net and public hospitals for health care access will be critical to stem these disparities.

Disparities in COVID-19 are consistent with patterns observed in cancer, particularly in African Americans where data are the most robust. Differences in cancer incidence, stage distribution, and mortality for African Americans compared with White Americans are well documented. For example, 5-year stage-specific survival from breast, colorectal, esophagus, kidney, liver, lung, melanoma, lymphoma, ovarian, bladder, cervical, uterine, and head and neck cancer are lower for African Americans compared with Whites (4). Causes of cancer disparities are multifactorial and include germline genetic susceptibility, but this risk can be enhanced or moderated by the macro- (socioeconomic and living conditions) and micro- (local microbiome, inflammation, toxin exposures) environment (5–7).

Cancer results from cellular genetic alterations yielding growth advantages over other cells, and the acquired ability to metastasize. The development of cancer as well as its biological behavior are shaped by environmental influences such as lifestyle choices or exposures. For instance, ingesting a high fat/high caloric diet, and prolonged use of tobacco and/or alcohol increase cancer risk by altering the lung and gut microbiome, thereby changing levels of systemic inflammation and immunity that ultimately influence genetic alterations in cells (5, 8, 9). In addition to modifying cancer risk, these lifestyle factors cause physiologic changes increasing risk for various interrelated comorbidities such as obesity and diabetes; asthma and chronic obstructive pulmonary disease; as well as hypertension, cardiovascular, and kidney disease (5, 7, 10, 11). These comorbidities can influence cancer treatment (12, 13) and have been correlated with adverse outcomes from cancer surgery, impaired ability to deliver effective chemotherapy, and radiation toxicity. Primary prevention of selected cancers can be achieved by avoiding known carcinogens such as tobacco, or by utilizing chemoprevention such as tamoxifen for patients at high risk for breast cancer. Substantial reductions in cancer burden are also attained through screening modalities for early detection of cervical, breast, colorectal, and prostate cancer (7, 14).

COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2. The virus enters respiratory (and other) cells via angiotensin-converting enzyme 2 (ACE2) receptors on the human cell surface (15). COVID-19 ranges phenotypically from completely asymptomatic to severe disease, with pulmonary,
COVID-19 and Cancer Disparity Similarities

Translational Relevance

Documented disparities in cancer incidence and mortality for racial and ethnic minorities and the medically underserved appear to be replicated with infection and survival outcome from coronavirus disease 2019 (COVID-19); the similarities are striking, with the underpinnings rooted in systemic socioeconomic disadvantages. Implementation of strategies to alleviate both cancer and COVID-19 disparities through governmental advocacy and action, hospital and community involvement, and provider and researcher participation must be proactively undertaken as a public health imperative. Adequate representation of racial and ethnic minorities in both cancer clinical trials and COVID-19 vaccine trials will boost confidence within those communities for uniform acceptance of results, enhance future clinical trial participation based on partnerships with the communities, and improve overall medical long-term compliance.

African American communities undermine social distancing efforts via reduced indoor space, limited open-air access, and smaller elevator sizes. These issues of increased residential housing density are particularly relevant in urban areas, where African American populations are more heavily concentrated. African Americans are more than three times as likely to use public transportation on a regular basis compared with White Americans.

While the genetic versus infectious etiologies of COVID-19 and cancer greatly differ, risk factors for outcome disparities in both diseases intersect with regard to comorbidities and socioeconomic disadvantage. The similarity of the pathogenesis, incidence, and mortality risks between cancer and COVID-19 (Fig. 1) is striking, with the similarities being due to the influence of circumstances create conditions that allow comorbidities to develop disproportionately in the African American population. These comorbidities place African Americans at higher risk for poor cancer outcomes, as well as at increased risk and severity for COVID-19 infection (Fig. 1). Cancer survivorship for African Americans has also been associated with reduced health-related quality of life. Long-term effects of COVID-19 are uncertain; lingering symptoms including fatigue, dyspnea, cognitive impairment, and renal sequelae. Risk factors for severe COVID-19 illness include older age, male gender, race/ethnicity, and preexisting comorbid diseases. Comorbidities further magnify disease severity within the other high-risk subsets of advanced-age and male patients. At present, treatment for COVID-19 is limited to supportive medical care, and primary prevention is promoted by avoiding infection through social distancing and use of personal protective equipment such as masks.

Fig. 1 Differences and overlap similarities for the pathogenesis, incidence, and mortality risks between cancer and COVID-19.
and tachy-arrhythmias have been reported (25). The 1918 Spanish flu experience revealed decades-later developmental effects on the birth cohort from that pandemic (26). The COVID-19-induced recession tripled unemployment rates between March and April 2020 (27). Modest evidence of recovery reflected in declining unemployment rates for June and July 2020 prompted some to describe a “V-shaped” economic rebound. Such an optimistic proclamation is premature in the face of the ongoing pandemic impact, and it completely overlooks the disproportionate and enduring effects of the COVID-19-induced recession on the African-American population. Unemployment rates for White Americans were 4.0%, 14.2%, and 9.2% in March, April, and July 2020, respectively; corresponding rates for African Americans were 6.7%, 16.7%, and 14.6% (27), with losses of employment-based insurance for these individuals and their dependents. Downstream adverse effects on COVID-19 and cancer care are then somewhat predictable with little medical insurance.

Safety-net and public hospitals deliver health care to patients that are underinsured or uninsured; these facilities are more highly concentrated in inner-city locations. African Americans comprise a substantial proportion of their patient population because of insurance factors as well as geography and household income and resources. Urban safety-net facilities are often located within African-American neighborhoods, thereby serving as employment hubs for these communities. The pandemic impact on safety-net hospitals was disproportionately devastating and initiated a disastrous cycle of worsening disparities for African Americans with regard to feasible options for both COVID-19 and cancer care. Costs of COVID-19 medical care became exorbitant for hospitals. Providing this care to patients that are unable to pay and that often have poorly controlled comorbidities has left many safety-net hospitals on the brink of bankruptcy (28, 29). When these facilities attempt returning towards pre–COVID-19 usual health care practices, they face challenges in catching up with cancer screening backlogs because of social distancing space and scheduling arrangements that were never designed to be optimized in these facilities (30). Many African Americans rely on safety-net institutions for routine medical care, COVID-19 care, and cancer care, further escalating their risk for health outcome disparities. The importance of safety-net institutions is also relevant to the discussion of clinical trial exclusion criteria that disproportionately affect African Americans; these facilities are underinsured or noninsured; these facilities are more highly concentrated in inner-city locations. African Americans comprise a substantial proportion of their patient population because of insurance factors as well as geography and household income and resources. Urban safety-net facilities are often located within African-American neighborhoods, thereby serving as employment hubs for these communities. The pandemic impact on safety-net hospitals was disproportionately devastating and initiated a disastrous cycle of worsening disparities for African Americans with regard to feasible options for both COVID-19 and cancer care. Costs of COVID-19 medical care became exorbitant for hospitals. Providing this care to patients that are unable to pay and that often have poorly controlled comorbidities has left many safety-net hospitals on the brink of bankruptcy (28, 29). When these facilities attempt returning towards pre–COVID-19 usual health care practices, they face challenges in catching up with cancer screening backlogs because of social distancing space and scheduling arrangements that were never designed to be optimized in these facilities (30). Many African Americans rely on safety-net institutions for routine medical care, COVID-19 care, and cancer care, further escalating their risk for health outcome disparities. The importance of safety-net institutions is also relevant to the discussion of clinical trial research for cancer as well as COVID-19. The regulatory, administrative, and personnel costs of medical research in humans is a huge financial burden for hospitals, and these expenses are often beyond the fiscal plans of safety-net facilities. Data regarding race-stratified outcomes in patients with both COVID-19 infection and cancer are limited at present. Recent studies have implicated germline genetics and epigenetics in the etiology of cancer disparities (10, 11); inflammatory pathways linked to these genetic patterns might also play a role in the cytokine storm linked to COVID-19 severity. A multicenter study of COVID-19 patients in New York City undergoing treatment for gynecologic oncology malignancies demonstrated higher mortality among the African-American cases, but this association was no longer present in multivariable modeling accounting for socioeconomic and comorbidities (31). As reviewed by Phillips and colleagues (32), African ancestral polymorphisms in ACE2 and acetylcholinesterase represent genetic patterns that have been correlated with comorbidities such as hypertension and diabetes; these genes contribute to COVID-19 infectivity and compound the difficulties of disentangling the effects of socioeconomic status, comorbidities, and race/ethnicity on COVID-19 outcomes. Research regarding the interplay of germline genetics and ancestry with cancer, comorbidities, and infectious disease is clearly warranted.

How can we mitigate disparities in cancer and COVID-19? Efforts to eliminate comorbidities such as obesity and diabetes are ideal, but have proven challenging on a population basis. We should also strive to reverse the systemic/structural disadvantages that exist for certain racial/ethnic populations and which establish conditions that predispose to comorbidities. Achieving health equity through improved access to educational and professional opportunities requires the will of the nation as well as political forces to enact broad-sweeping antiracism programs. In the short term, we suggest several strategies that can be implemented at the federal and local government levels, the hospital and community levels, and the provider and research levels to address COVID-19 disparities and lessen the downstream pandemic-induced recession consequences on cancer disparities (Table 1). Important “lessons learned” in cancer research include the facts that inadequate diversity in contemporary clinical trial accruals is largely secondary to provider-level impediments with failure to offer participation opportunities to African Americans and comorbidity exclusion criteria that disproportionately affect African Americans; these problems will need to be addressed in COVID-19 research. Efforts to

<table>
<thead>
<tr>
<th>CANCER</th>
<th>CANCER and COVID-19</th>
<th>COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Race/ethnic minority populations should be targeted for aggressive cancer screening programs as access to these services return in the post–COVID-19 era to prevent deterioration of prior gains in screening.</td>
<td>Cancer clinical trials teams should leverage community engagement and patient navigator networks to ensure diverse accrual onto COVID-19 testing, treatment, and vaccine studies.</td>
<td>COVID-19 research proposals should be designed a priori with disparities-related research questions, such as correlative science studies looking at genetic ancestry.</td>
</tr>
<tr>
<td>The cancer community must work proactively to protect cancer disparity research projects and community outreach/education efforts in the post–COVID-19 era of budget constraints. Disparities in research and health education efforts targeting diverse communities must not be perceived as expendable items.</td>
<td>Public hospitals (which were disproportionately devastated by the costs of COVID-19 pandemic care) must be supported so that they can meet the safety-net health care needs of communities that are disproportionately represented among the medically underserved.</td>
<td>Health insurance coverage opportunities such as expanded Medicaid programs should be made readily available to financially constrained individuals that lost their employment-based coverage as a consequence of the COVID-19 pandemic.</td>
</tr>
<tr>
<td>Cancer-related advocacy organizations that provide community engagement activities addressing disparities should be supported.</td>
<td>Need for improved access to technologies and devices that support telehealth services to reach minority populations.</td>
<td>COVID-19 vaccine and treatment trials should be statistically designed to oversample racial/ethnic minority populations, so that results can be generalized with confidence.</td>
</tr>
</tbody>
</table>
improve diversity in the accrual of patients to cancer and COVID-19 research are necessary so that results can be generalized with confidence, and these efforts deserve to be supported through creative investments by academia, industry, and federal funding sources into safety-net institutions to: (i) develop enduring relationships and infrastructure with safety-net hospitals in diverse communities, (ii) increase diversity representation in clinical trials, and (iii) be financially feasible for safety-net hospitals to conduct meaningful clinical trials. Issues such as the “digital divide” that exist between racial/ethnic communities create barriers to effective telehealth and video visits. COVID-19 has had a dual effect on undermining cancer outreach programs of health care institutions and professional advocacy organizations; the pandemic-induced recession has reduced revenue overall, and fundraising efforts such as walkathons and public events that depend on large gatherings for their success are not feasible in the context of social distancing policies.

The health care community and the population-at-large need to be cognizant of similarities in risk for COVID-19 as well as cancer disparities, and eliminating these disparities should be a public health imperative.

**Authors’ Disclosures**
R.A. Winn reports personal fees from Genentech, as well as nonfinancial support and other from LUNGevity and American Cancer Society outside the submitted work. No disclosures were reported by the other authors.

**Acknowledgments**
L.A. Newman is supported by the Susan B. Komen Foundation (SAC160072) and Fashion Footwear Association of New York Charitable Foundation. R.A. Winn is supported by the U.S. Public Health Service (US40CA202997 and US44MD025253). J.M. Carethers is supported by the U.S. Public Health Service (R01CA206010) and the A. Alfred Taubman Medical Research Institute of the University of Michigan.

Received August 29, 2020, revised September 30, 2020, accepted October 8, 2020, published first October 13, 2020.

**References**


23. Duque RB. Black health matters too… especially in the era of Covid-19: how poverty and race converge to reduce access to quality housing, safe neighborhoods, and health and wellness services and increase the risk of co-morbidities associated with global pandemics. J Racial Ethn Health Disparities 2020 Sep 18 [Epub ahead of print].


